Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO Subscriptions PDA Services My JCO Customer Service

Journal of Clinical Oncology, Vol 25, No 16 (June 1), 2007: pp. 2262-2269
© 2007 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2006.09.6297

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Timmers, H. J.L.M.
Right arrow Articles by Pacak, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Timmers, H. J.L.M.
Right arrow Articles by Pacak, K.

Superiority of Fluorodeoxyglucose Positron Emission Tomography to Other Functional Imaging Techniques in the Evaluation of Metastatic SDHB-Associated Pheochromocytoma and Paraganglioma

Henri J.L.M. Timmers, Anna Kozupa, Clara C. Chen, Jorge A. Carrasquillo, Alexander Ling, Graeme Eisenhofer, Karen T. Adams, Daniel Solis, Jacques W.M. Lenders, Karel Pacak

From the Reproductive Biology and Medicine Branch, National Institutes of Child Health and Human Development; Nuclear Medicine Department; Department of Diagnostic Radiology; Clinical Neurocardiology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; Department of Internal Medicine, Division of General Internal Medicine; and the Department of Endocrinology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands

Address reprint requests to Henri J.L.M. Timmers, MD, PhD, Reproductive Biology and Medicine Branch, National Institute of Child Health and Human Development, 10 Center Dr, Bldg 10, CRC, RM 1-E 3140, MSC 1109, Bethesda MD 20892-1109; e-mail: h.timmers{at}endo.umcn.nl

Purpose: Germline mutations of the gene encoding subunit B of the mitochondrial enzyme succinate dehydrogenase (SDHB) predispose to malignant paraganglioma (PGL). Timely and accurate localization of these aggressive tumors is critical for guiding optimal treatment. Our aim is to evaluate the performance of functional imaging modalities in the detection of metastatic lesions of SDHB-associated PGL.

Patients and Methods: Sensitivities for the detection of metastases were compared between [18F]fluorodopamine ([18F]FDA) and [18F]fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET), iodine-123- (123I) and iodine-131 (131I) -metaiodobenzylguanidine (MIBG), 111In-pentetreotide, and Tc-99m-methylene diphosphonate bone scintigraphy in 30 patients with SDHB-associated PGL. Computed tomography (CT) and magnetic resonance imaging (MRI) served as standards of reference.

Results: Twenty-nine of 30 patients had metastatic lesions. In two patients, obvious metastatic lesions on functional imaging were missed by CT and MRI. Sensitivity according to patient/body region was 80%/65% for 123I-MIBG and 88%/70% for [18F]FDA-PET. False-negative results on 123I-MIBG scintigraphy and/or [18F]FDA-PET were not predicted by genotype or biochemical phenotype. [18F]FDG-PET yielded a by patient/by body region sensitivity of 100%/97%. At least 90% of regions that were false negative on 123I-MIBG scintigraphy or [18F]FDA-PET were detected by [18F]FDG-PET. In two patients, 111In-pentetreotide scintigraphy detected liver lesions that were negative on other functional imaging modalities. Sensitivities were similar before and after chemotherapy or 131I-MIBG treatment, except for a trend toward lower post- (60%/41%) versus pretreatment (80%/65%) sensitivity of 123I-MIBG scintigraphy.

Conclusion: With a sensitivity approaching 100%, [18F]FDG-PET is the preferred functional imaging modality for staging and treatment monitoring of SDHB-related metastatic PGL.

Supported by the Intramural Research Program of the National Institute of Child Health and Human Development/National Institutes of Health.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.




This article has been cited by other articles:


Home page
JNMHome page
K. P. Koopmans, J. W. B. de Groot, J. T.M. Plukker, E. G.E. de Vries, I. P. Kema, W. J. Sluiter, P. L. Jager, and T. P. Links
18F-Dihydroxyphenylalanine PET in Patients with Biochemical Evidence of Medullary Thyroid Cancer: Relation to Tumor Differentiation
J. Nucl. Med., April 1, 2008; 49(4): 524 - 531.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
A. Karagiannis, D. P Mikhailidis, V. G Athyros, and F. Harsoulis
Pheochromocytoma: an update on genetics and management
Endocr. Relat. Cancer, December 1, 2007; 14(4): 935 - 956.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
H. J.L.M. Timmers, J. A. Carrasquillo, M. Whatley, G. Eisenhofer, C. C. Chen, A. Ling, W. M. Linehan, P. A. Pinto, K. T. Adams, and K. Pacak
Usefulness of Standardized Uptake Values for Distinguishing Adrenal Glands with Pheochromocytoma from Normal Adrenal Glands by Use of 6-18F-Fluorodopamine PET
J. Nucl. Med., December 1, 2007; 48(12): 1940 - 1944.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 Site Map

Copyright © 2007 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online